Avid Bioservices Inc (CDMO)

[itsabouttime]

A little snip from a Fierce Biotech article


Durvalumab is AstraZeneca's most important pipeline product and the company said last year, during its bid defense against a takeover attempt by Pfizer, that the medicine could eventually generate annual sales of $6.5 billion, making it a key component of an overall $45 billion sales forecast for 2023.

While ATLANTIC is looking at durvalumab's use on its own in a subset of late-stage lung cancer patients, Soriot said the drug's real promise lay in combining it with other products to help a much wider range of patients.